Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.21+0.05 (+1.20%)
Close on Nov 13, 2026Market cap $449.08MP/E –Yield –
Relmada Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Relmada Therapeutics's total assets was $205.30M at Sep 30, 2026. For fiscal 2025 it was $94.00M, up 105.2% from the year before. The highest annual figure on record is $223.33M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.00M | +105.2% |
| FY2024 | Dec 31, 2024 | $45.82M | -53.0% |
| FY2023 | Dec 31, 2023 | $97.55M | -36.2% |
| FY2022 | Dec 31, 2022 | $152.91M | -31.5% |
| FY2021 | Dec 31, 2021 | $223.33M | +2085.2% |
| FY2019 | Jun 30, 2019 | $10.22M | +235.3% |
| FY2018 | Jun 30, 2018 | $3.05M | +7.4% |
| FY2017 | Jun 30, 2017 | $2.84M | -72.3% |
| FY2016 | Jun 30, 2016 | $10.24M | +182.0% |
| FY2013 | Dec 31, 2013 | $3.63M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $205.30M | +1280.0% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $219.06M | +937.4% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $235.36M | +750.3% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $94.00M | +105.2% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $14.88M | -73.3% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $21.12M | -70.3% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $27.68M | -67.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $45.82M | -53.0% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $55.72M | -48.9% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $71.03M | -41.8% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $84.41M | -37.7% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $97.55M | -36.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $109.15M | -41.7% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $122.04M | -46.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $135.57M | -39.3% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $152.91M | +68.1% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $187.12M | +68.9% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $225.81M | +117.4% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $223.33M | +2085.2% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $90.93M | +3392.5% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $110.77M | +3257.8% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $103.87M | +6575.2% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $10.22M | +235.3% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $2.60M | -45.7% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $3.30M | -49.8% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.56M | -72.3% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $3.05M | +7.4% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $4.80M | +15.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $6.57M | +5.6% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $5.61M | -29.1% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $2.84M | -72.3% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $4.17M | -67.2% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $6.23M | -62.5% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $7.92M | -61.3% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $10.24M | +182.0% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $12.72M | +103297.1% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $16.60M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $20.48M | – |
| Q4 FY2013CQ4 2013 | Dec 31, 2013 | $3.63M | – |
| Q1 FY2013CQ1 2013 | Nov 30, 2013 | $12.30K | – |
See a number that looks wrong?